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BACKGROUND
Oncological treatments are traditionally administered via intravenous injection by qualified personnel. Oral formulas, which are developing rapidly, are 
much preferred by patients and facilitate administration, however they may increase non-adherence. In this prospective monocenter non randomized 
study four common oral chemotherapeutics were given to 40 patients divided into 4 groups according to oral treatments (letrozole/exemestane, imatinib, 
sunitinib, capecitabine). The aim of this study was to evaluate adherence and to offer these patients interdisciplinary support with the joint help of doctors 
and pharmacists.
MATERIALS AND METHODS
We present here results for capecitabine and aromatase inhibitors. Adherence 
was evaluated in 19 patients split into 2 groups using persistence (defined as 
time (days) spent between inclusion and discontinuation of treatment) and 
quality of execution (defined as correspondence between medication take and 
prescribed regimen) as measurements. Evaluation included measurement of 
these parameters using MEMS (medication event monitoring system) as 
well as classical oncological follow-ups and semi-structured interviews. The 
patients were monitored for the entire duration of treatment up to a maximum of 
1 year. Patient satisfaction was estimated at the end of the monitoring period 
using a standardized questionnaire. 
Naoux, Aardex group
CONCLUSION
The persistence and quality of execution observed in our capecitabine, letrozole and exemestane patients were excellent as expected compared to 
previously published studies. The interdisciplinary approach allowed us to better identify and help patients with toxicities to maintain adherence. Overall 
patients were content with the interdisciplinary follow-up. A longer follow up would allow better evaluation of the full impact of our method. The 
interpretation of the results of the ongoing inclusions in the other groups will provide us necessary informations for an update analysis.
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Intake hours
P
e
rc
e
n
ta
g
e
0 2 4 6 8 10 12 14 16 18 20 22 24
0
5
10
15
20
25
30
[07:00 am ; 08:00 am]
Persistence
Study days
P
er
ce
nt
ag
e 
of
 p
at
ie
nt
s
0 100 200 300 400
0
20
40
60
80
100
Persistence after 180 days: 
85.26%
The questionnaire at the end of monitoring allowed us to document patient satisfaction for the interviews offered (57% useful, 28% very useful, 15% 
useless)  and the success in integrating MEMS into their daily lives ( 57% very easily, 43% easily). 
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141 (range 3-406)Median FU duration
AI: aromatase inhibitor, EOX: epirubicine-oxaliplatine-xeloda, Xelox: xeloda-oxaliplatine, 
FU: follow up
Hand-foot syndrom (1pt)
Acute coronary syndrom (1pt)
Toxicities > grade 3
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Capecitabine mono (3pts)
Capecitabine-lapatinib (1pt)
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Treatment regimen
11 women : 8 menSex
55 (range 38-77)Median age
Patients characteristics (n=19)
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